Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union

Journal of Health Economics

Volumn 23, Issue 5, 2004, Pages 1035-1057

  Ganslandt, Mattias ^a   Maskus, Keith E ^b  

^a RESEARCH INSTITUTE OF INDUSTRIAL ECONOMICS IFN   (Sweden)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug pricing; F12; I11; International arbitrage; L12; Parallel imports; Pharmaceutical products

Indexed keywords

COMPETITION (ECONOMICS); IMPORT; MARKET CONDITIONS; PRICE DETERMINATION; PRICING POLICY;

ARTICLE; DATA ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; HEALTH CARE COST; HEALTH CARE POLICY; PROSPECTIVE PRICING;

COMMERCE; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; EUROPE; EUROPEAN UNION; HUMANS; INTERNATIONALITY; LEGISLATION, DRUG; MODELS, ECONOMETRIC; SWEDEN;

EURASIA; EUROPE; NORTHERN EUROPE; SCANDINAVIA; SWEDEN;

EID: 4444349464     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2004.03.005     Document Type: Article

References (15)

1. Richard, C.E., Whinston, M.D., Hurwitz, M.A., 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics, pp. 1-66.
2. CEC, 1998. Commission Communication on the Single Market in Pharmaceuticals, COM(98)588 final, Brussels, November 1998.
3. Danzon P.M. The economics of parallel trade. PharmacoEconomics. 13:1998;293-304
4. Danzon, P., Chao, L., 1995. The Uses and Abuses of International Price Comparisons, in Helms Competitive Strategies in the Pharmaceutical Industry. AEI Press, Washington.
5. Danzon P., Chao L. Cross-national price differences for pharmaceuticals: how large, and why? Journal of Health Economics. 19:2000;159-195
6. Frank R.G., Salkever D.S. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal. 59:1992;165-179
7. Frank R.G., Salkever D.S. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy. 6:1997;75-90
8. Ganslandt, M., Maskus, K.E., 2000. Parallel imports of pharmaceutical products. Mimeo. IUI, Stockholm, Sweden.
9. Ganslandt, M., Maskus, K.E., 2001. Parallel imports of pharmaceutical products in the European Union. World Bank Policy Research Working Paper 2630, July 2001.
10. Grabowski H.G., Vernon J.M. Brand loyalty. Journal of Law and Economics. 35:1992;331-350
11. Holmberg, C., Kiellberg, H., Andersson, B., 2003. Distribution of pharmaceutical products in the Nordic countries. SSE/EFI Working Paper Series in Business Administration No. 2003: 10.
12. Lu Z.J., Comanor W.S. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics. 80:1998;108-118
13. Pecorino P. Should the US allow prescription drug reimports from Canada? Journal of Health Economics. 21:2002;699-708
14. Wiggins, S.N., Maness, R., 1994. Price competition in pharmaceutical markets. Department of Economics, Texas A&M University. Unpublished manuscript.
15. World Health Organization, 2001. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. WHO, Geneva.